

Neurocrine Biosciences Inc (NBIX) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/N56C7CD346BEN.html>

Date: February 2021

Pages: 54

Price: US\$ 125.00 (Single User License)

ID: N56C7CD346BEN

Abstracts

Neurocrine Biosciences Inc (NBIX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Neurocrine Biosciences Inc (Neurocrine) discovers, develops and commercializes pharmaceutical products for the treatment of neurologic, psychiatric and endocrine related diseases and disorders. Its lead product, Ingrezza (valbenazine) capsule is a US FDA approved selective vesicular monoamine transporter 2 inhibitor for the treatment of adults with tardive dyskinesia (TD). Its other major pipeline products include elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis and uterine fibroids and opicapone, a catechol-O-methyltransferase inhibitor (COMT inhibitor) intended for adult patients with Parkinson's disease. It also develops drug candidates for the treatment of essential tremor and classic congenital adrenal hyperplasia. Neurocrine is headquartered in San Diego, California, the US.

Neurocrine Biosciences Inc Key Recent Developments

Feb 04,2021: Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results

Jan 08,2021: Neurocrine Biosciences provides preliminary fourth quarter and full-year 2020 net product sales results and 2021 program milestones

Nov 09,2020: Neurocrine Biosciences reports third quarter 2020 financial results

Oct 07,2020: Neurocrine Biosciences and Me2/Orchestra, in partnership with mental health advocacy groups, honor Mental Illness Awareness Week by launching monumental moments , an online community platform and charitable initiative
Aug 03,2020: Neurocrine Biosciences reports second quarter 2020 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

Table of Contents

List of Tables

List of Figures

SECTION 1 - ABOUT THE COMPANY

Neurocrine Biosciences Inc - Key Facts

Neurocrine Biosciences Inc - Key Employees

Neurocrine Biosciences Inc - Key Employee Biographies

Neurocrine Biosciences Inc - Major Products and Services

Neurocrine Biosciences Inc - History

Neurocrine Biosciences Inc - Company Statement

Neurocrine Biosciences Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview

Neurocrine Biosciences Inc - Business Description

Neurocrine Biosciences Inc - Corporate Strategy

Neurocrine Biosciences Inc - SWOT Analysis

SWOT Analysis - Overview

Neurocrine Biosciences Inc - Strengths

Neurocrine Biosciences Inc - Weaknesses

Neurocrine Biosciences Inc - Opportunities

Neurocrine Biosciences Inc - Threats

Neurocrine Biosciences Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Neurocrine Biosciences Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 04, 2021: Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results

Jan 08, 2021: Neurocrine Biosciences provides preliminary fourth quarter and full-year 2020 net product sales results and 2021 program milestones

Nov 09, 2020: Neurocrine Biosciences reports third quarter 2020 financial results

Oct 07, 2020: Neurocrine Biosciences and Me2/Orchestra, in partnership with mental health advocacy groups, honor Mental Illness Awareness Week by launching monumental moments , an online community platform and charitable initiative

Aug 03, 2020: Neurocrine Biosciences reports second quarter 2020 financial results

Jun 17, 2020: Takeda licences psychiatry programmes to Neurocrine Biosciences

May 06, 2020: Neurocrine Biosciences reports first quarter 2020 financial results

Apr 03, 2020: Neurocrine Biosciences provides COVID-19 business update

Feb 04, 2020: Neurocrine Biosciences reports fourth quarter and full-year 2019 financial results

Feb 03, 2020: Neurocrine Biosciences announces appointment of Shalini Sharp to Board of Directors

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Neurocrine Biosciences Inc, Key Facts
Neurocrine Biosciences Inc, Key Employees
Neurocrine Biosciences Inc, Key Employee Biographies
Neurocrine Biosciences Inc, Major Products and Services
Neurocrine Biosciences Inc, History
Neurocrine Biosciences Inc, Subsidiaries
Neurocrine Biosciences Inc, Key Competitors
Neurocrine Biosciences Inc, Ratios based on current share price
Neurocrine Biosciences Inc, Annual Ratios
Neurocrine Biosciences Inc, Annual Ratios (Cont...1)
Neurocrine Biosciences Inc, Annual Ratios (Cont...2)
Neurocrine Biosciences Inc, Interim Ratios
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Neurocrine Biosciences Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Neurocrine Biosciences Inc, Performance Chart (2016 - 2020)

Neurocrine Biosciences Inc, Ratio Charts

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

COMPANIES MENTIONED

Prometheus Laboratories Inc

Pfizer Inc

Newron Pharmaceuticals SpA

Lundbeck LLC

GlaxoSmithKline Inc

Eli Lilly and Co

Auspex Pharmaceuticals Inc

AbbVie Inc

I would like to order

Product name: Neurocrine Biosciences Inc (NBIX) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/N56C7CD346BEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N56C7CD346BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970